SS-31 (Elamipretide) (SS31)

Mitochondria-targeted tetrapeptide that improves mitochondrial function and reduces oxidative stress. In clinical trials for heart failure.

Key Data

Research Status

Clinical trials

Half-Life

~1 hour

Administration

Subcutaneous or IV injection

Typical Dosage

0.25-4 mg/kg

Mechanism of Action

Targets cardiolipin in mitochondrial inner membrane, stabilizing electron transport and reducing ROS production.

Reported Benefits

• Mitochondrial function
• Cardiac protection
• Reduced oxidative stress
• Exercise capacity

All information is presented for Research Use Only (RUO). Not medical advice.